Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Epizyme, Inc.
Cambridge, Massachusetts, United Statesepizyme.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Epizyme's lead medicine Tazverik (tazemetostat) received FDA Accelerated Approval in 2020 for relapsed or refractory follicular lymphoma and epithelioid sarcoma. The company also has EZM0414, a SETD2 inhibitor with FDA Fast Track status in Phase I/Ib trials for multiple myeloma and diffuse large B-cell lymphoma[1][4].
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculesepigenetic therapies
- Industry
- Biotech
02
Partnerships
GSK (terminated)Genentech (clinical trial combinations)
Beyond the preview
Go deeper on Epizyme, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epizyme, Inc..